Results 151 to 160 of about 285,383 (314)

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching   +20 more
wiley   +1 more source

Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Epithelial ovarian cancer (EOC) is a severe malignancy with few effective treatment options. While the mechanisms remain unclear, changes in lipid metabolism may fuel tumor growth and EOC progression, offering a possible path for new treatments.
Hitomi Sakaguchi‐Mukaida   +10 more
wiley   +1 more source

Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? While treatment strategies for solid brain metastases have been relatively uniform across cancer subtypes, tailored approaches are warranted. In this observational study, intracranial recurrences after microsurgical resection occurred significantly earlier and more frequently at distant sites in patients with triple‐negative breast cancer ...
Jonathan Weller   +14 more
wiley   +1 more source

Nationwide audit of cervical cancer screening reveals unsatisfactory triage strategies and trends over time in incidence among cytology negative women

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This population‐based cohort study aimed to demonstrate how annual audits of all aspects of the cervical cancer screening pathway can be performed using register national data with clinical validation to identify patterns of risk and inform program change.
Cecilia Kärrberg   +9 more
wiley   +1 more source

Correction: Genetic risk stratification and risk factors of early menopause in women: a multi-center study utilizing polygenic risk scores. [PDF]

open access: yesFront Endocrinol (Lausanne)
Zhong W   +24 more
europepmc   +1 more source

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon   +5 more
wiley   +1 more source

Pilot Implementation of a National, Web-Based Abortion Curriculum for Obstetrics-Gynecology Residents. [PDF]

open access: yesO G Open
Mengesha B   +7 more
europepmc   +1 more source

Trends in the incidence of cancers of the breast and female genital tract in Harare, Zimbabwe 1990–2019

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cancers of the breast and female genital tract represent more than half of all cancers in women in sub‐Saharan Africa. Here, the authors assessed incidence trends in a female population living in urban sub‐Saharan Africa based on the Zimbabwe National Cancer Registry in Harare over a 30‐year period.
Eric Chokunonga   +7 more
wiley   +1 more source

Correction: Evaluation of the topographic classification of placenta accreta spectrum: protocol for an ongoing prospective multicenter study. [PDF]

open access: yesBMC Pregnancy Childbirth
Nieto-Calvache AJ   +32 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy